Modern Therapy of Chronic Myeloid Leukaemia
<p id="p1">The advent of tyrosine kinase inhibitors (TKIs) has transformed CML from a fatal disease into a manageable chronic condition. This review aims to provide a comprehensive overview of the current therapeutic landscape for CML and discuss the unique challenges in the treatment of CML, partic...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2024
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/89694 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | <p id="p1">The advent of tyrosine kinase inhibitors (TKIs) has transformed CML from a fatal disease into a manageable chronic condition. This review aims to provide a comprehensive overview of the current therapeutic landscape for CML and discuss the unique challenges in the treatment of CML, particularly in resource-limited settings such as Kenya. The introduction of TKIs marked a paradigm shift in the management of CML. Imatinib, the first-generation TKI, demonstrated remarkable efficacy in inducing durable cytogenetic and molecular responses, establishing it as the gold standard for first-line therapy. However, resistance and intolerance to imatinib necessitated the development of new drugs as dasatinib, nilotinib, bosutinib, ponatinib, and asciminib have been introduced. Despite these advancements, significant challenges persist in the management of CML in developing countries like Kenya. The high cost of TKIs, limited healthcare infrastructure, and scarcity of specialised medical professionals are formidable barriers to optimal treatment. In conclusion, the therapeutic landscape of CML has evolved dramatically with the advent of TKIs and novel agents, offering hope for achieving long-term disease control and even treatment-free remission. However, the disparity in access to these therapies between developed and developing countries underscores the need for global health strategies to ensure equitable treatment.</p> |
|---|---|
| ISBN: | 978-1-83768-298-0 |
| DOI: | 10.5772/intechopen.115458 |